Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03285152 | A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients | completed | N/A | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04387227 | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05410509 | "Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)" | completed | N/A | 25 | University of Alabama at BirminghamOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05940298 | Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06641219 | Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen | completed | Phase 1 | 7 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01251861 | Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 2 | Jun 25, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT02217709 | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | completed | Phase 2 | 26 | University of Southern CaliforniaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03326713 | Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project(GRACE) | completed | N/A | 668 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04530552 | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05185947 | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 3 | 506 | National Cancer Institute (NCI)NIH | 2 | Jun 24, 2026 | clinicaltrials |
| NCT03114826 | Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients(VE-CART) | completed | — | 272 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03641560 | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 4 | 52 | Astellas Pharma IncINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04018053 | 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy | completed | Early Phase 1 | 16 | Brigham and Women's HospitalOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04746638 | Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04817501 | Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System(CTCs) | completed | — | 150 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06101927 | Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06359964 | Infective Complications in TP Biopsy Without Antibiotic Prophylaxis | completed | N/A | 1,753 | Chinese University of Hong KongOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06386653 | Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06874985 | Effectiveness and Impact of the Lived Experience Cancer Awareness Campaign on Screening Participation | completed | N/A | 1,264 | International Agency for Research on CancerOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT00326898 | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery(ASSURE) | completed | Phase 3 | 1,943 | National Cancer Institute (NCI)NIH | 3 | Jun 23, 2026 | clinicaltrials |
| NCT04919512 | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder(SunRISe-4) | completed | Phase 2 | 163 | Janssen Research & Development, LLCINDUSTRY | 10 | Jun 23, 2026 | clinicaltrials |
| NCT05368207 | Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient(Pemb-HT) | completed | N/A | 1 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06243510 | Comparison of Apixaban Versus Enoxaparin(CARE) | completed | N/A | 126 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06660147 | Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer(KELI-PAOLA) | completed | — | 243 | ARCAGY/ GINECO GROUPOTHER | 2 | Jun 23, 2026 | clinicaltrials |
| NCT01802242 | Tumor TARGET Prostate Cancer | completed | N/A | 85 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02848768 | Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma(RTKI) | completed | — | 45 | Rennes University HospitalOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02854982 | Impact on Quality of Life 3 Years After Diagnosis of Prostate Cancer(EPICAP-QALY) | completed | — | 900 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06213571 | Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas | completed | N/A | 80 | Mayo ClinicOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02885974 | Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer(BLAST) | completed | Phase 1 | 22 | Baylor College of MedicineOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03294083 | A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 95 | SillaJen, Inc.INDUSTRY | 3 | Jun 18, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07655648 | Dual-tracer PET Radiomics for Prostate Cancer Stratification | completed | — | 100 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657299 | Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study | completed | — | 30 | Ain Shams UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03263650 | Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04751929 | Abemaciclib With or Without Atezolizumab for mCRPC | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05721326 | Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition | completed | N/A | 1,283 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07653191 | Changes in Uterine Artery Resistance Index Following Cervical Conization | completed | N/A | 50 | Adana City Training and Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03455452 | Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer(WITNESS) | completed | — | 623 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03677544 | Predictive Factorsfor Final Pathologic Ureteral Sections(CYSTECTOMEN) | completed | — | 748 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04941768 | An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION) | completed | — | 105 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 4 | Jun 16, 2026 | clinicaltrials |
| NCT04944550 | New Models for the Evaluation of Preclinical Treatment for Urothelial Carcinomas of the Upper Excretory Tract.(CICLOP) | completed | — | 20 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05617885 | Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | completed | Phase 1 | 9 | Praful Ravi, MB BCHir, MRCPOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651020 | The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors | completed | — | 1 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03630536 | TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative | completed | — | 28 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05605964 | Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate | completed | Phase 3 | 387 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05858749 | A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC). | completed | — | 494 | PfizerINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648745 | Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer(CEBOC) | completed | Phase 2 | 30 | Prof Gordon JaysonOTHER | 1 | Jun 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 29, 2026source: clinicaltrials